Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.37 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652996 | 0.77 | PTGS2 (0.47) | PTGDR | |
| SCHEMBL2655331 | 0.77 | HSP90AA1 (0.59) | — | |
| SCHEMBL2654413 | 0.75 | PTGDR2 (0.51) | PTGDR2OPRL1F2RL1PTGDRPTPRB | |
| SCHEMBL2652954 | 0.75 | PTGS2 (0.45) | — | |
| SCHEMBL16585059 | 0.74 | BACE1 (0.39) | — | |
| SCHEMBL2653857 | 0.73 | PNMT (0.37) | — | |
| SCHEMBL2568282 | 0.69 | NUDT1 (0.51) | PTGDR2OPRL1F2RL1PTGDR | |
| SCHEMBL3634608 | 0.68 | PTGDR2 (0.46) | PTGDR2OPRL1F2RL1PTGDR | |
| SCHEMBL11773147 | 0.68 | KDM1A (0.52) | PTGDR2OPRL1F2RL1 | |
| SCHEMBL8785689 | 0.67 | PTGDR2 (0.48) | PTGDR2OPRL1F2RL1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |